Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

@article{Kollmannsberger2007SunitinibTF,
  title={Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.},
  author={Christian K. Kollmannsberger and Denis Souli{\'e}res and Rita M.-Y. Wong and Antonella Scalera and Rania Gaspo and Georg Bjarnason},
  journal={Canadian Urological Association journal = Journal de l'Association des urologues du Canada},
  year={2007},
  volume={1 2 Suppl},
  pages={S41-54}
}
Sunitinib, a new vascular endothelial growth factor receptor inhibitor, has demonstrated high activity in renal cell carcinoma (RCC) and is now widely used for patients with metastatic disease. Although generally well tolerated and associated with a low incidence of common toxicity criteria grade 3 or 4 toxicities, sunitinib exhibits a distinct pattern of novel side effects that require monitoring and management. This article summarizes the most important side effects and proposes… CONTINUE READING
51 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

Similar Papers

Loading similar papers…